What is the latest INDRAMEDCO stock price?
The latest stored price for INDRAMEDCO is Rs 374.55 as of 2026-07-20.
gimli
INDRAMEDCO stock AI analysis
INDRAMEDCO Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
INDRAPRASTHA MEDICAL CORP is a small-cap stock in Healthcare. This Gimli page shows the latest available INDRAMEDCO price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹374.55
1W return
-1.15%
1M return
-2.19%
3M return
-9.35%
6M return
-2.90%
1Y return
-23.19%
Market cap
₹3,433.61 cr
PE
18.70
PB
4.64
ROE
+27.47%
ROCE
+26.19%
RSI
44.78
Turnover
₹4.99 cr
Why it can matter in screens
- Momentum: INDRAMEDCO is below 50DMA, below 200DMA; RSI is 44.78.
- Returns: 1D +1.01%, 1W -1.15%, 1M -2.19%, 3M -9.35%, 1Y -23.19%.
- Trend levels: 52W high ₹622.80, 52W low ₹349.50, off high -39.86%.
- Liquidity: latest turnover is ₹4.99 cr; volume vs 20D is +0.93%.
- Valuation/profitability: PE 18.70, PB 4.64, ROE +27.47%, ROCE +26.19%.
- Growth: 3Y sales CAGR +11.66%, 3Y profit CAGR +28.69%.
Quick Answers
Is INDRAMEDCO above its 50DMA and 200DMA?
INDRAMEDCO is below 50DMA, below 200DMA. The latest 50DMA is 382.87 and the latest 200DMA is 435.84.
What are INDRAMEDCO PE, ROE and ROCE?
INDRAMEDCO has PE 18.70, ROE +27.47%, and ROCE +26.19% in Gimli's latest available snapshot.
How has INDRAMEDCO performed recently?
INDRAMEDCO has returned -2.19% over 1 month, -9.35% over 3 months, and -23.19% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 364.81 cr | 67.84 cr | 41.70 cr | 4.55 |
| 2025-12-31 | 371.61 cr | 69.10 cr | 41.00 cr | 4.47 |
| 2025-09-30 | 388.40 cr | 78.68 cr | 49.46 cr | 5.40 |
| 2025-06-30 | 365.06 cr | 80.05 cr | 51.46 cr | 5.61 |
| 2025-03-31 | 333.75 cr | 67.67 cr | 41.01 cr | 4.47 |
| 2024-12-31 | 324.93 cr | 57.32 cr | 32.81 cr | 3.58 |
| 2024-09-30 | 349.82 cr | 69.69 cr | 42.40 cr | 4.63 |
| 2024-06-30 | 347.86 cr | 72.24 cr | 44.77 cr | 4.88 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,482.51 cr | 295.67 cr | 183.62 cr | 20.03 |
| 2025-03-31 | 1,356.36 cr | 266.92 cr | 160.99 cr | 17.56 |
| 2024-03-31 | 1,204.06 cr | 207.25 cr | 123.96 cr | 13.52 |
| 2023-03-31 | 1,064.95 cr | 156.91 cr | 86.15 cr | 9.40 |
| 2022-03-31 | 891.28 cr | 114.62 cr | 58.62 cr | 6.39 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 991.36 cr | 4.93 cr | 36.86 cr | 740.37 cr |
| 2025-03-31 | 851.62 cr | 61.48 cr | 32.76 cr | 596.68 cr |
| 2024-03-31 | 723.24 cr | 61.60 cr | 33.95 cr | 477.76 cr |
| 2023-03-31 | 555.14 cr | 52.26 cr | 2.48 cr | 379.45 cr |
| 2022-03-31 | 461.71 cr | 41.74 cr | 5.31 cr | 325.44 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 167.44 cr | 107.79 cr | n/a |
| 2025-03-31 | 156.75 cr | 120.42 cr | n/a |
| 2024-03-31 | 200.15 cr | 130.76 cr | n/a |
| 2023-03-31 | 144.47 cr | 99.89 cr | n/a |
| 2022-03-31 | 94.30 cr | 64.82 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +51.00% | +2.44% | +0.88% | +0.01% | +45.69% | +0.00% |
| 2025-12-31 | +51.00% | +2.73% | +0.83% | +0.00% | +45.44% | +0.00% |
| 2025-09-30 | +51.00% | +2.41% | +3.51% | +2.62% | +43.08% | +0.00% |
| 2025-06-30 | +51.00% | +2.72% | +3.56% | +2.62% | +42.72% | +0.00% |
| 2025-03-31 | +51.00% | +2.94% | +3.56% | +2.62% | +42.51% | +0.00% |
| 2024-12-31 | +51.00% | +2.88% | +3.19% | +2.65% | +42.93% | +0.00% |
| 2024-09-30 | +51.00% | +2.64% | +3.20% | +2.66% | +43.16% | +0.00% |
| 2024-06-30 | +51.00% | +1.70% | +3.15% | +2.61% | +44.15% | +0.00% |
| 2024-03-31 | +51.00% | +1.08% | +4.91% | +0.00% | +43.01% | +0.00% |
| 2023-12-31 | +51.00% | +0.95% | +6.37% | +0.00% | +41.68% | +0.00% |
| 2023-09-30 | +51.00% | +0.80% | +6.71% | +0.00% | +41.49% | +0.00% |
| 2023-06-30 | +51.00% | +0.37% | +0.00% | +0.00% | +48.62% | +0.00% |
| 2023-03-31 | +51.00% | +0.27% | +0.00% | +0.00% | +48.72% | +0.00% |
| 2022-12-31 | +51.00% | +0.77% | +0.00% | +0.00% | +48.22% | +0.00% |
| 2022-09-30 | +51.00% | +0.15% | +0.02% | +0.00% | +48.83% | +0.00% |
| 2022-06-30 | +51.00% | +0.00% | +0.11% | n/a | n/a | +0.00% |
| 2022-03-31 | +51.00% | +0.00% | +0.16% | n/a | n/a | +0.00% |
| 2021-12-31 | +51.00% | +0.00% | +0.20% | n/a | n/a | +0.00% |
| 2021-09-30 | +51.00% | +0.00% | +0.05% | n/a | n/a | +0.00% |
| 2021-06-30 | +51.00% | +0.00% | +0.02% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 469,405.90 cr | 40.823336 | +14.71% | +15.52% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,269.92 cr | 75.650281 | +16.19% | +8.71% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 169,405.46 cr | 78.319677 | +17.18% | +42.14% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,040.28 cr | 65.380043 | +21.03% | +21.93% |
| CIPLA | CIPLA LTD | 116,452.52 cr | 30.005339 | +11.79% | -2.75% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,616.29 cr | 23.056854 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 113,320.96 cr | 21.221472 | +26.83% | +28.27% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,290.40 cr | 74.382732 | +14.33% | -9.32% |
Try these prompts
- Analyze INDRAPRASTHA MEDICAL CORP with valuation, momentum and industry peers
- Compare INDRAMEDCO with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare INDRAMEDCO with other Healthcare stocks
Data snapshot: 2026-07-20. Not investment advice.